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Abstract
AIM: To analyze the available evidence about the risk 
of extrapancreatic malignancies and pancreatic ductal 
adenocarcinoma associated to pancreatic intraductal 
papillary mucinous tumors (IPMNs).
METHODS: A systematic search of literature was 
undertaken using MEDLINE, EMBASE, Cochrane and 
Web-of-Science libraries. No limitations for year of 
publication were considered; preference was given 
to English papers. All references in selected articles 
were further screened for additional publications. Both 
clinical series and Literature reviews were selected. For 
all eligible studies, a standard data extraction form was 
filled in and the following data were extracted: study 
design, number of patients, prevalence of pancreatic 
cancer and extrapancreatic malignancies in IPMN 
patients and control groups, if available.
RESULTS: A total of 805 abstracts were selected and 
read; 25 articles were considered pertinent and 17 
were chosen for the present systematic review. Eleven 
monocentric series, 1 multicentric series, 1 case-
control study, 1 population-based study and 3 case 
report were included. A total of 2881 patients were 
globally analyzed as study group, and the incidence of 
pancreatic cancer and/or extrapancreatic malignancies 
ranged from 5% to 52%, with a mean of 28.71%. 
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When a control group was analyzed (6 papers), the 
same incidence was as low as 9.4%.
CONCLUSION: The available Literature is unanimous in 
claiming IPMNs to be strongly associated with pancreatic 
and extrapancreatic malignancies. The consequences in 
IPMNs management are herein discussed.
Key words: Intraductal papillary mucinous neoplasm; 
Pancreas; Diagnosis; Follow-up; Tumors; Computed 
tomography scan; 18FDG-PET
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Core tip: This paper enter a clinical debate which has real 
relevance in the daily practice in the field of pancreatic 
cystic neoplasm, as a number of asymptomatic intraductal 
papillary mucinous tumors (IPMNs) are diagnosed every 
day by abdominal imaging, and the actual most common 
clinical attitude provides for a weak diagnostic pathway. 
However, in the light of an unanimous literature, this 
attitude would be a while dangerous, as up to 30%-40% 
of IPMN cases would develop a second malignancy in 
their life. The same should be underlined when discussing 
the follow-up protocols.
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INTRODUCTION
Intraductal papillary mucinous tumors (IPMNs) belong 
to the group of cystic neoplasms of the pancreas, 
and are characterized by a communication with 
the Wirsung duct and by the absence of ovarian-
type stroma[1]; the cystic expansion of the main or a 
branch pancreatic duct is due to a papillary growth 
of the epithelium, with rich mucin production. IPMNs 
were firstly described in 1982[2], and subsequently 
classified as adenoma, borderline or carcinoma (in situ 
or invasive) tumors[3,4]. In the following years, from a 
number of clinical series[5-9] based both upon surgical 
treatment[10-13] and radiological follow-up[14-17], clinical 
and pathological features characteristic of IPMNs clearly 
emerged: the neoplasm is symptomatic in many 
cases, recurrent acute pancreatitis without recognised 
biliary or alcoholic etiology being the most frequent 
expression. The diagnosis is based on CT and MRI 
imaging, which further distinguish 2 different variants, 
the main duct tumor (MDT) and the branch duct 
tumor (BDT), having different incidence of malignancy 
and prognosis. The natural history of IPMNs remains 
partially unclear. At diagnosis, 10%-20% of cases 
harbour invasive carcinoma, 10%-20% in situ 
carcinoma and the remaining 60%-80% intraductal or 
intracystic papillomatosis with simple dysplasia. In the 
published series, resectability was 90%-100%, while 
mortality and morbidity were similar to those related 
to pancreatic surgery for ductal adenocarcinoma; 
5-year survival is 100% for adenomas and border-
line tumours, 80%-90% for in situ carcinomas and 
50%-70% for invasive carcinomas.
One of the most surprising and most interesting 
characteristic of IPMNs is to be frequently associated 
with other neoplasms, both pancreatic and extrapan-
creatic. Some initial reports of this feature date back 
at least 20 years ago[18], and were later confirmed 
by numerous studies. Though it is not yet known 
the underlying mechanism, however this figure 
substantially has never been questioned ever since; 
it has been reported that patients affected by IPMN 
would be more likely to die of other neoplasm than 
from IPMN itself[17]; of course this entails major 
practical implications, particularly with respect to the 
diagnostic phase and to the follow-up.
The present article discusses the literature focused 
on this subject, and commits the clinical questions, to 
date unsolved, resulting therefrom.
MATERIALS AND METHODS
Search methods
A systematic search of literature was performed 
using MEDLINE, EMBASE, Cochrane and Web-of-
Science libraries. No limitations for year of publication 
were considered. Search terms were: IPMN, IPMN-
associated cancers, extrapancreatic neoplasm. MeSH 
terms were: Adenocarcinoma, Mucinous/diagnosis, 
Adenocarcinoma, Mucinous/surgery, Adenocarcinoma, 
Mucinous/prognosis, Pancreas/pathology, Pancreatic 
Neoplasms/diagnosis, Pancreatic Neoplasms/prognosis, 
Pancreatic Neoplasms/surgery.
Preference has been given to English publications, but 
abstracts from other languages were also included. All 
references in selected articles were further screened for 
additional publications. Articles were retrieved according 
to the Preferred Items for Reporting of Systematic 
Reviews and Meta-Analyses guidelines (Figure 1).
Study selection
Articles were selected if their abstract showed an 
association between IPMN and pancreatic adenocar-
cinoma and/or extrapancreatic neoplasms before, after 
or at the same time of IPMN diagnosis. Both clinical 
series and Literature reviews were selected. Papers 
reporting genetic characteristic or proteomic assessment 
in IPMN, studies of risk factors for malignancy, congress 
presentations and letters to the editor were excluded.
Data extraction
For all eligible studies, a standard data extraction form 
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was filled in and the following data were extracted: 
study design, number of patients, prevalence of 
pancreatic cancer (PC) and extrapancreatic malignancies 
(EPM) in IPMN patients and control groups, if available. 
For statistical analysis, it was considered significant aP < 
0.05, when published.
RESULTS
The titles and abstracts of a total of 805 articles were 
screened separately by 2 authors (Gian Luca Baiocchi, 
Sarah Molfino) for eligibility. Out of these, 780 articles 
were excluded, either for having abstract unavailable 
(n = 30), or for reporting risk factors for malignancy 
(n = 90), or being irrelevant to our topic (n = 355), or 
because they described other features such as genetic 
proteomic assessment of IPMN (n = 203); excluded 
congress presentations and letters to the editor were 
102. This resulted in 25 articles, 8 of which were further 
excluded after full text examination, either for being 
narrative review (n = 1), or comments to other papers (n 
= 4), or only available in abstract form (n = 3).
The remaining 17 articles were fully analyzed and 
data were extracted as summarized in Table 1[19-35].
A total of 2881 patients were globally analyzed 
as study group, and the mean incidence of PC/EPM 
was 28.71%. When a control group was analyzed (6 
papers), the same incidence was as low as 9.4%.
The majority of studies are retrospective (n = 11), 
while a case-control study and a multicentric-cohort 
were also included. Prevalence of PC/EPM in patients 
with IPMN was 14.1%-52%, with the exception of 
Uehara et al[35] (2008), reporting a prevalence of 
PC of only 5% (but this paper does not consider the 
extrapancreatic malignancies). Another paper reporting 
a somewhat lower incidence of EPM was published in 
2007 by Riall and Coll.; in this study data of more than 
18500 patients with pancreatic cancer were collected 
from the SEER Tumor Registry, and in this group the 
incidence of EPM was compared between patients with 
pancreatic adenocarcinoma and patients with IPMN. 
Thus, only malignant or invasive IPMNs were included.
Six studies reported a control group analysis; in all 
of them, a significantly higher prevalence of PC/EPM 
in IPMN patients than in control-group was reported; 
furthermore, in all the studies the incidence of EPM 
exceeded the expected rate of the same malignancies in 
the general population. When reported, in the majority 
of cases, the extrapancreatic neoplasm associated to 
IPMN patients were colorectal cancers (3%-12%).
DISCUSSION
Pancreatic IPMNs are observed with increasing 
frequency in asymptomatic patients[36], and still 
represent in the majority of cases a clinical dilemma. 
Identifyng the small subgroup pf malignant cases is 
of upmost importance: from one side, resecting all 
the IPMNs cases would represent an over-treatment 
in more than 75% of patients, but on the other side 
unrecognising malignancy would significantly worsen 
the prognosis of those cases. Thus, while in presence 
of clear malignant features the surgical indication 
is supported by good survival results, nevertheless 
805 publications screened
25 publications eligible
17 publications included:
      1 population-based study
      11 retrospective analysis
      3 case report
      1 case-control study
      1 multicentric-cohort study
780 publications excluded:
      30 non-English
      90 risk factors
      350 irrelevant
      203 IPMN-genetic or proteomic assessment
      102 congress presentation and letters to the editor
8 publications excluded:
      1 narrative review
      4 irrelevant
      3 abstract
Figure 1  Articles retrieval strategy, according to the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses guidelines.
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Table 1  Studies reporting pancreatic cancer and extrapancreatic malignancies incidence in patients with intraductal papillary 
mucinous tumors
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a number of controversies remain for IPMNs at low 
risk of malignancy, relative to the diagnostic protocol 
to be adopted and to the surgical indication. Finally, 
it remains still not clear what kind of follow-up is 
indicated in both patients with resected IPMN and 
patients not submitted to surgery, as the likelihood of 
developing malignant recurrence and of progress into 
malignancy, respectively, is very low from the available 
series.
Comprehensive imaging, including ultrasonography 
(US) and contrast-enhanced US, CT scan, magnetic 
resonance cholangiopancreatography (MRCP) and 
endoscopic ultrasound, is highly sensitive and very 
low specific (down to about 20%[37]) in recognising 
malignancy, when the Sendai criteria, evidence-based 
treatment guidelines, published by a consortium of the 
International Association of Pancreatology in 2006 and 
2012[38,39], are strictly applied. Endo-US fine-needle 
cytology significantly increases the specificity, but it is 
fairly invasive. 18FDG-PET was also investigated in a 
few published series, whit a reported accuracy rate of 
85%-95%[40-44], and a specificity rate up to 100%[37]. 
However, Sendai guidelines do not take into account 
18FDG-PET, which is besides very expensive and finally 
poorly employed in the majority of Centres.
When evaluating a rationale strategy for IPMNs 
staging and follow-up, an important and unique 
feature should be taken into consideration: it appears 
from the Literature that patients harbouring IPMNs are 
at higher risk of developing a second malignancy, both 
before, concurrent or after IPMN diagnosis[17,18].
An extensive literature search does not reveal 
a clear aetiopathogenetic explanation. The merely 
assumption that patients, once diagnosed to harbor 
IPMN, are subjected to instrumental examinations 
which therefore detect with greater frequency other 
malignancies, is not confirmed either by the fact that 
most of the associated tumors were diagnosed before 
the IPMN, either because the examination currently 
regarded as the gold standard for IPMNs, namely the 
MRCP, is an organ-specific and much less panoramic 
test compared to other investigations (including 
CT, which is less often used for the great number 
of necessary examinations and then the elevated 
radiation dose). The only speculative indications come 
from the analysis of risk factors for PC/EPC in IPMNs: 
female gender, white race, and above all advanced 
age [as early as 55-64 years, but with a peak to 
75-84 years; for this age group the odds ratio for EPM, 
compared to the general population, is as high as 4.0 
(95%CI: 2.4-6.7)]. Very few studies sought to analyze 
the molecular characteristics of IPMNs cases with PC/
EPC; among them, Lee and Coll. found only correlation 
with the expression of the MUC2 gene and not of other 
genes, including p53[45]. As in other fields of oncology, 
the thorough study of patients with IPMN and 
associated malignancies would provide an interesting 
model for the study of carcinogenesis. Unfortunately, 
Ref. Year Study design n  
(IPMN)
Prevalence 
EPM
Colon 
Ca
Gastric 
Ca
NET Group 23 n  
(group 2)
Prevalence 
EPM - group 
2 (%)
P  vaule
Lubezky et al[19] 2012 Retrospective   82   20% 31% NR NR Pancreatic ductal 
adenocarcinoma
    150   6    0.002
Riall et al[20] 2007 Population-based 992   10%   3% 0.1% NR Other neoplasm1 18655 10 NS
Yoon et al[21] 2008 Retrospective 210      33.8%   7%  14% NR Non-ipmn 
cystic pancreatic 
neoplasm
    175 12 < 0.001
Kamisawa et al[22] 2005 Retrospective   79   35%   9%  15% NR
Ishida et al[23] 2008 Retrospective   61      24.6%   8%  10% NR
Ishida et al[24] 2013 Case report     1 100% 0 0 100
Goh et al[25] 2006 Case report     3 100% 0 0 100
Eguchi et al[26] 2006 Retrospective   69   42% 12%    6% NR Other neoplasm2     301 12 < 0.001
Choi et al[27] 2006 Retrospective   61   39%   7%  13% NR Other pancreatic 
neoplasm
      38   8 < 0.001
Calculli et al[28] 2010 Retrospective 142      14.1% NR
Reid-Lombardo et al[29] 2010 Retrospective 471   52%   4% 0 NR
Oh et al[30] 2009 Retrospective   37   38%   8%    8% NR
Baumgaertner et al[31] 2008 Case-control 178   17% 10% NR NR Aged and 
gender-matched 
control
    356 8.4    0.003
Tanno et al[32] 1999 Retrospective   42   48% 12%  10% NR
Larghi et al[33] 2013 Multicentric 
cohort
390      23.6%    12.4% NR NR
Tewari et al[34] 2013 Case report     3 100% 0 0 100%
Uehara et al[35] 2008 Retrospective   60 54 NR NR NR
1Data from SEER Tumor Registry; 2Data from Osaka Cancer Registry; 3Control-group, if present; 4Pancreatic adenocarcinoma. NR: Not reported; IPMN: 
Intraductal papillary mucinous tumors.
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currently available data does not allow the precise 
identification of the subset of IPMN patients at greater 
risk of developing PC/EPM. Even in patients with small 
BDT, high incidences have been reported.
The most significant claim coming from the analysis 
of this data, to some extent surprising and still partially 
unexplained, concerns the clinical pathway. Indeed, 
the concept that at least one third of patients with 
IPMN develop in the course of their live PC/EPM cannot 
be overlooked. The first implication is related to the 
initial management of patients with newly diagnosed 
IPMN. There is currently a strong tendency to consider 
the BDT- IPMNs, without clinical and radiological signs 
which lead them in groups “high risk stigmata” and 
“worrisome features” according to Sendai guidelines, 
a disease of limited clinical relevance, for which no 
further investigation are warranted[46]. Although such a 
trend appears to be fully justified regarding the IPMN 
itself, what is described in the present paper leads 
to a reflection about the opportunity to submit these 
patients to instrumental examinations whit total-body 
value.
The second consideration concerns the IPMNs at 
high risk of malignancy (“high risk stigmata” according 
to Sendai): in these cases, since surgery is frequently 
performed, it might be smart to subject the patients to 
an even more comprehensive diagnostic preoperative 
work-up, including for example a colonoscopy and 
gastroscopy, in sight of a possible combined intervention.
The third consideration refers to the follow-up 
protocols: despite the low risk of malignant dege-
neration of resected IPMNs, and of not resected IPMNs 
without Sendai criteria, it appears at least careless to 
abandon these patients and end the follow-up, even 
though it is clearly expensive.
Of course, the points made above have conse-
quences on the most widely used imaging modality 
in IPMNs: in addition to the MRCP, other panoramic 
examinations such as thorax-abdomen contrast medium 
enhanced CT and 18FDG-PET become relevant.
In conclusion, the literature appear unanimous 
in reporting that patients with IPMNs have a high 
risk, in the order of at least 30%, to develop PC and 
EPM; hence the opportunity to deepen, at the time of 
the first finding, and in any case preoperatively, the 
search for such tumors; and to maintain an high index 
of suspicion, and a constant follow-up, in all IPMNs 
patients, with total body examinations.
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